PRTA
Prothena Corporation plc
NASDAQ · Healthcare · Biotechnology · IE
$9.82
+2.29%Year over year
Reported trailing growth
- Revenue
- +427.3%
- EBITDA
- +83.1%
- EBIT
- +77.7%
- EPS
- +85.3%
- Free cash flow
- +68.5%
- Operating cash flow
- +68.8%
Forward estimates
Based on analyst estimates
- Revenue
- -31.8%
- EBITDA
- -0.9%
- EPS
- +0.5%
Three-year CAGR
- Revenue
- -43.6%
- EBITDA
- -54.0%
- EBIT
- -19.4%
- Net income
- -99.6%
- EPS
- -99.6%
- Free cash flow
- -8.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026